Tevogen Inc. Stock-Based Compensation
Tevogen Inc. (TVGN) reported Stock-Based Compensation of $6.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Tevogen Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.29M, a 1.52% increase year-over-year.
- Tevogen Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.85M, a 60.93% decline year-over-year.
- Tevogen Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.45M, a 64.86% decline year-over-year.
- Tevogen Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.24M, a 2.49% decline year-over-year.
- Tevogen Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $16.22M, a 60.20% decline from fiscal 2024.
- Tevogen Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $40.76M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $6.14M 10-Q · filed 2026-08-14 | $8.58M derived: sum of 3 quarters · filed 2026-08-14 | $11.83M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $2.85M 10-Q · filed 2026-05-15 | $5.30M derived: sum of 2 quarters · filed 2026-05-15 | $8.54M derived: sum of 3 quarters · filed 2026-05-15 | $11.78M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.69M derived: sum of 2 quarters · filed 2026-03-31 | $8.93M derived: sum of 3 quarters · filed 2026-08-14 | $16.22M 10-K · filed 2026-03-31 |
| 2025-09-30 | $3.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.48M derived: sum of 2 quarters · filed 2026-08-14 | $13.78M 10-Q · filed 2025-11-14 | $20.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $10.53M 10-Q · filed 2026-08-14 | $17.49M derived: sum of 3 quarters · filed 2026-08-14 | $20.82M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $7.29M 10-Q · filed 2026-05-15 | $14.25M derived: sum of 2 quarters · filed 2026-05-15 | $17.58M derived: sum of 3 quarters · filed 2026-05-15 | $21.72M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $10.29M derived: sum of 2 quarters · filed 2026-03-31 | $14.43M derived: sum of 3 quarters · filed 2026-03-31 | $40.76M 10-K · filed 2026-03-31 |
| 2024-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $7.47M derived: sum of 2 quarters · filed 2025-11-14 | $33.80M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $4.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $30.48M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $26.33M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |